FIGURE 5.

Residual survival free from insulin initiation by age at randomization. Age‐based Kaplan‐Meier curves are displayed for patients aged, A, 45, B, 60, and C, 75 years for insulin‐free survival between the empagliflozin and placebo arms. Area under the survival curve (up to a maximum of 90 years) reflected average time alive and free from insulin initiation. The difference in these survival time estimates is the time that empagliflozin prolongs lifespan without the need for insulin initiation among insulin‐naïve patients